Get started
Author

Yuya Oishi

Observed name: YUYA OISHI
ORCID: 0009-0009-0610-1156
Observed ORCID: 0009-0009-0610-1156
OpenAlex ID: A5136380582
Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma
2026 · Mamoru Hashimoto, Lan Inoki, et al. · International Journal of Clinical Oncology · 1
PDF
Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated With Adjuvant Nivolumab
2026 · Asuka Sano, Yuya Oishi, et al. · Urologia Internationalis
Impact of baseline renal function on the clinical outcomes and safety of adjuvant nivolumab in high-risk urothelial carcinoma: a multicenter retrospective real-world study
2026 · Asuka Sano, Yuya Oishi, et al. · BMC Urology
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy.
2026 · Shinya Watanabe, Yuto Matsushita, et al. · PubMed
Multimodal Treatment for Female Primary Urethral Carcinoma: A Three‐Case Series Utilizing Robot‐Assisted Radical Cystectomy and Extended Resection
2026 · Yuya Oishi, Hiromitsu Watanabe, et al. · IJU Case Reports
Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma
2026 · YUYA OISHI, YUTO MATSUSHITA, et al. · Anticancer Research
Enfortumab vedotin demonstrates consistent efficacy in platinum- and ICI-refractory metastatic urothelial carcinoma patients irrespective of prior response: a multicenter real-world study
2026 · Shunsuke Watanabe, Yuichi Kitagawa, et al. · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication
PDF
Works count: 7
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type